Deferoxaminmesilat

DFOM · desferal · DESFERRIOXAMINE MESYLATE · deferoxaminebmesylate · Desferioxamine mesylate · desferrioxamine mesilate · DEFEROXAMINE MESYLATE SALT · Deferoxamine for system suitability

https://huagongshe.com/de/chemical/62881

Identifikatoren & physikalische Daten

CAS No.	138-14-7
Summenformel	C26H52N6O11S
Durchschnittliche Molmasse	656,8 g/mol
Monoisotopische Masse	656,34147748 g/mol
SMILES	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN.CS(=O)(=O)O
InChIKey	IDDIJAWJANBQLJ-UHFFFAOYSA-N
PubChem CID	62881
ChEMBL	CHEMBL1234
EC No.	205-314-3
DTXSID	DTXSID6037649
Lokaler Name	Deferoxaminmesilat

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	269
H-Brücken-Donoren	7
H-Brücken-Akzeptoren	12
Frei drehbare Bindungen	23
Schwere Atome	44
Formalladung	0
Komplexität	832
Human Drugs	FDA approved drugs -> Active ingredient
Collision Cross Section	221.4 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Schmelzpunkt	148-149°
Lagerbedingungen	2-8°C
Löslichkeit	H2O: 50 mg/mLSoluble to 100 mM in water
Aggregatzustand	powder
Farbe	white to off-white
InChIKey	IDDIJAWJANBQLJ-UHFFFAOYSA-N
SMILES	C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C.S(=O)(=O)(O)C

Sicherheit & Vorschriften

GHS-Einstufung	This chemical does not meet GHS hazard criteria for 30% (3 of 10) of reports.DangerH315 (60%): Causes skin irritation [Warning Skin corrosion/irritation]P203, P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 10 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Regulatorische Informationen	Desferrioxamine B mesylate: Does not have an individual approval but may be used under an appropriate group standard
Weitere Sicherheitsinformationen	IMAP assessments - Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate (salt): Environment tier I assessment
Hazard Classes and Categories	Skin Irrit. 2 (60%)
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)Deferoxamine mesylatevLess-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015
Wassergefährdungsklasse (WGK)	2
Zollcode	29280000
RTECS-Nr.	UG5310000
Toxizität	man,TDLo,parenteral,16gm/kg/34W-I (16000mg/kg),CARDIAC: PERICARDITISGASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINEBLOOD: OTHER CHANGES,American Journal of Kidney Diseases. Vol. 10, Pg. 71, 1987.
Sicherheitshinweise (S)	22-24/25
Lagerklasse	11 - Combustible Solids

Anwendungen & Verwendung

Beschreibung

Deferoxamine is a bacterial siderophore that chelates iron. It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 μM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia. Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.

Verwenden

DEFEROXAMINE MESYLATE is an iron chelating agent used in therapy for patients with sickle cell diseases and iron overload. Studies suggest that it can exert potential antioxidant neuroprotective effects in stroke patients